Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An adenocarcinoma that arises from the endocervix. It is the most common type of endocervical adenocarcinoma. The neoplastic epithelium shows a pseudostratified architecture and the malignant cells have enlarged, elongated, and hyperchromatic nuclei.
Biomarker and diagnostic research for endocervical adenocarcinoma has been reported in the published literature.
19 clinical trials registered, 6 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 2 PHASE3, 7 PHASE2, 7 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07454642](https://clinicaltrials.gov/study/NCT07454642) |
Data assembled from 3 of 12 sources · Last updated Oct 3, 2026, 8:12 PM UTC
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors |
PHASE1 |
Avacta Life Sciences Ltd |
RECRUITING |
[NCT07020117](https://clinicaltrials.gov/study/NCT07020117) | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | PHASE1 | Aktis Oncology, Inc. | RECRUITING |
[NCT07276360](https://clinicaltrials.gov/study/NCT07276360) | Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda | PHASE2 | Uganda Cancer Institute | RECRUITING |
[NCT05686226](https://clinicaltrials.gov/study/NCT05686226) | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | PHASE2 | Christian Hinrichs | RECRUITING |
[NCT05639972](https://clinicaltrials.gov/study/NCT05639972) | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | PHASE1 | Christian Hinrichs | RECRUITING |
167 publications have been identified in PubMed for endocervical adenocarcinoma. Research spans Diagnostic / Biomarker (31%), Basic Science / Preclinical (21%), and Case Report / Case Series (20%).
Research Type | Count | % of Total |
|---|---|---|
Testing and diagnosis research | 51 | 31% |
Laboratory research | 35 | 21% |
Patient case studies | 34 | 20% |
Disease patterns and progression | 21 | 13% |
Research summaries | 14 | 8% |
Clinical study results | 5 | 3% |
New treatment approaches | 5 | 3% |
Other research | 2 | 1% |
Chen Y (2026). [PMID: 40968751](https://pubmed.ncbi.nlm.nih.gov/40968751/). *J Gynecol Oncol*. [Basic Science / Preclinical]
Gui N (2026). [PMID: 42262621](https://pubmed.ncbi.nlm.nih.gov/42262621/). *Discov Oncol*. [Diagnostic / Biomarker]
Hasbay E (2026). [PMID: 41758898](https://pubmed.ncbi.nlm.nih.gov/41758898/). *PLoS One*. [Basic Science / Preclinical]
Wang X (2026). [PMID: 41966556](https://pubmed.ncbi.nlm.nih.gov/41966556/). *Cancer Treat Res Commun*. [Diagnostic / Biomarker]
Yoshida H (2026). [PMID: 41745365](https://pubmed.ncbi.nlm.nih.gov/41745365/). *J Pers Med*. [Review / Meta-Analysis]
Li J (2026). [PMID: 41578469](https://pubmed.ncbi.nlm.nih.gov/41578469/). *Medicine (Baltimore)*. [Diagnostic / Biomarker]
Lin S (2026). [PMID: 41612311](https://pubmed.ncbi.nlm.nih.gov/41612311/). *BMC Cancer*. [Diagnostic / Biomarker]
Lim H (2026). [PMID: 41965228](https://pubmed.ncbi.nlm.nih.gov/41965228/). *Int J Gynecol Cancer*. [Epidemiology / Natural History]
Xu R (2026). [PMID: 41128548](https://pubmed.ncbi.nlm.nih.gov/41128548/). *J Natl Cancer Inst*. [Epidemiology / Natural History]
Yasutake N (2026). [PMID: 41424299](https://pubmed.ncbi.nlm.nih.gov/41424299/). *Histopathology*. [Epidemiology / Natural History]